EndocrinologyCo-secretion of Cortisol and Aldosterone in Individuals With Resistant Hypertension: Results From the MOMENTUM TrialSloan et al. • 2026 • AACE April 24, 2026
EndocrinologyRelacorilant Treatment Improves Glycemic Control Among Individuals With Cushing Syndrome (Endogenous Hypercortisolism) and Hyperglycemia on Glucagon-Like Peptide-1 Receptor Agonists: Insights From a Phase 3 StudySilverstein et al. • 2026 • AACE April 24, 2026
OncologyReal-World Comparative Effectiveness of Nab-Paclitaxel and Paclitaxel in Combination with Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer (COMPASS)Coleman et al. • 2026 • SGO April 13, 2026
OncologyRelacorilant Plus Nab-Paclitaxel Demonstrates a Progression-Free Survival Benefit in Ovarian Cancer Independent of Tumor Glucocorticoid Receptor (GR) Expression LevelsLorusso et al. • 2026 • SGO April 13, 2026
OncologyBELLA: A Phase 2 Study of Relacorilant + Nab-Paclitaxel +/- Bevacizumab in Patients with Gynecologic CancersLorusso et al. • 2026 • SGO April 13, 2026
OncologyFinal Overall Survival Results from the Phase 3 ROSELLA Trial: Relacorilant Plus Nab-Paclitaxel vs Nab-Paclitaxel Monotherapy in Patients with Platinum-Resistant Ovarian Cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023)Lorusso et al. • The Lancet • Olawaiye et al. • SGO • 2026 April 10, 2026
EndocrinologyPrevalence and Clinical Impact of Hypercortisolism in Patients With Resistant Hypertension: Primary Results From the MOMENTUM StudyBhatt et al. • 2026 • ACC.26 March 28, 2026
EndocrinologyEfficacy and Safety of Relacorilant for the Treatment of Patients With Cushing’s Syndrome (GRACE): A Multicentre, Phase 3, Double-Blind, Placebo-Controlled, Randomised-Withdrawal StudyPivonello • 2026 • The Lancet Diabetes & Endocrinology February 20, 2026
